Ep. 171 - 2Q Markets Preview, Abortion Drug Rulings, Gilead Oncology
BioCentury This Week
00:00
The TL1A Antibody Market: A Competitive Process
I think that 75% premium also points to the fact that pretty confident this was probably a very competitive process. And I think we should also acknowledge that this particular product is against a new target meaning that there isn't a product that is marketed against this target. But that it also opens up a wide range of indications. So it's not just this asset against that one indication that they're paying for. There's obviously a lot of potential in that. It's going to be an exciting space to watch as well.
Transcript
Play full episode
